Intraventricular morphine produces pain relief, hypothermia, hyperglycaemia and increased prolactin and growth hormone levels in patients with cancer pain.
The effects of analgesic, thermoregulatory and endocrine functions of administering morphine sulphate (0.3 mg) into the lateral cerebral ventricle via an Ommaya catheter were assessed in eight patients with cancer pain. Satisfactory control of intractable pain was obtained in these patients, without any change in other sensory modalities. The delay in the onset of pain relief and the duration of analgesia ranged, respectively, from 20 to 40 min and from 12 to 16 h after drug injection. In addition, intraventricular administration of morphine caused a reduction in rectal temperature in these patients at an ambient temperature of 24 degrees C. The hypothermia in response to the injection of morphine was due to cutaneous vasodilation and sweating. There was no change in metabolism or in respiratory evaporative heat loss after morphine injection. Further, 10 to 20 min after intraventricular administration of morphine, the blood levels of prolactin, growth hormone and glucose were elevated in these patients. The changes in temperature and endocrine levels lasted for 1-3 h. In addition to the pain relief, these side-effects of morphine treatment were short-lasting and disappeared as the morphine treatment continued. The results indicate that activation of opiate receptors in the brain produced pain relief, hypothermia (due to cutaneous vasodilation and sweating), and increased blood levels of prolactin, growth hormone and glucose in patients with cancer pain.
Department of Surgery, National Defense Medical Center, Taipei, Taiwan, Republic of China.
C F
CF
Su
M Y
MY
Liu
M T
MT
Lin
D000328:Adult; D000368:Aged; D001833:Body Temperature Regulation / Q000187:drug effects; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D007035:Hypothermia / Q000139:chemically induced*; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism; D010148:Intractable Pain / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood*
D009020:Morphine; D011388:Prolactin; D013006:Growth Hormone